Kuria Therapeutics Closes Initial Funding Round
- Kuria Therapeutics, a Little Rock, Ark.-based pharmaceutical company developing novel ophthalmic and dermal therapeutics, closed its first fundraising round
- The amount of the deal was not disclosed
- The company intends intends to use the funds to advance R&D activities to support ongoing preclinical development activities ahead of a planned Series A raise
- This round will support selection of a lead ophthalmic formulation, preclinical proof-of-concept studies, and initiation of key manufacturing activities for IND-enabling work and future clinical studies
- KuriaTherapeutics is a pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic and dermal disease
- Its lead product candidate is a topical ophthalmic formulation of SCO-116, a novel Nrf2 activator being developed under a license from Scohia Pharma
